Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Reexamination Certificate
2011-06-21
2011-06-21
Henley, III, Raymond J (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
C514S365000
Reexamination Certificate
active
07964584
ABSTRACT:
The present invention relates to a pharmaceutical composition for preventing and treating osteoporosis, comprising N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}benzamidine, 4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}benzamidine, or salts thereof, and alendronic acid or a salt thereof.As a prophylactic or therapeutic composition for osteoporosis, the combination treatment of N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}benzamidine, 4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}-benzamidine, or salts thereof and alendronic acid or a salt thereof exhibits excellent inhibitory effect on osteoclast differentiation, as compared to each individual treatment, thereby being useful for the prevention or treatment of osteoporosis.
REFERENCES:
patent: 4407761 (1983-10-01), Blum et al.
patent: 4621077 (1986-11-01), Rosini et al.
patent: 4705651 (1987-11-01), Staibano
patent: 5039819 (1991-08-01), Kieczykowski
patent: 5159108 (1992-10-01), Kieczykowski
patent: 2010/0029596 (2010-02-01), Ryu et al.
patent: 2003-0008654 (2003-01-01), None
patent: WO-01/28564 (2001-04-01), None
Andrew S Neviaser et al, “Low-Energy Femoral Shaft Fractures Associated With Alendronate Use”, Journal of Orthopedic Trauma, 2008, 22(5), 346-350.
Lindsay et al, “Addition of Alendronate to Ongoing Hormone Replacement Therapy in the Treatment of Osteoporosis: A Randomized, Controlled Clinical Trail”, J. Clin Endocrinol. Metab. 84, 3073-3081 (1999).
Johnell et al, “Additive Effects of Raloxifene and Alendronate on Bone Density and Biochemical Markeser of Bone Remodeling in Postmenopausal Women with Osteoporosis”, J. Clin. Endocrinol. Metab. 87, 985-992 (2002).
Greenspan et al, “Combination Therapy With Hormone Replacement and Alendronate for Prevention of Bone Loss in Elderly Women: A Randomized Controlled Trail”, JAMA, 289, 2525-2533 (2003).
Black et al, “The Effects of Parathyroid Hormone and Alendronate Alone or in Combination in Postmenopausal Osteoporosis”, N. Eng. J. Med. 349, 1207-1215, (2003).
Finkelstein et al, “The Effects of Parathyroid Hormone Alendronate, or Both in Men with Osteoporosis”, N. Eng. J. Med. 349, 1216-1226, (2003).
Lee, Sung-Eun, “Design, Synthesis, and Evaluation of functional Molecules for the Treatment of LTB4 Related Disease and Electroluminescent Device”, Synthesis and Biological Activity of Natural Products and Designed New Hybrid Compounds for the Treatment of LTB4 Related Disease, Busan National University, a thesis for a Ph. D degree, 1999. 8.
Chung Duk Kyun
Hwang Yun-Ha
Lee Jin Soo
Park Jae Hoon
Ryu Jei Man
Arent & Fox LLP
Dong Wha Pharmaceutical Co., Ltd.
Henley, III Raymond J
LandOfFree
Method of treating or preventing osteoporosis comprising... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating or preventing osteoporosis comprising..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating or preventing osteoporosis comprising... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2646025